FDA Issues Warning Letter to Best Chinese Medicines LLC Over Five Unapproved Drug Products

A September 2026 website review by FDA's Center for Drug Evaluation and Research (CDER) has resulted in a formal warning letter to Best Chinese Medicines LLC, citing five products marketed with disease treatment and physiological claims that trigger drug classification under section 201(g)(1) of the FD&C Act, without the approved new drug applications those claims require.

The five products named in reference number 738556 are "Dissolve Mass Stasis Breaker," "Gynostemma Leaf (Penta) Jiao Gu Lan," "Wenxin Keli," "Lianhua Qingwen Capsules," and "Duhuo Jisheng Wan." FDA documented labeling language across product pages and blog posts asserting effects including tumor dissipation, LDL cholesterol reduction, and blood pressure control. Under 21 CFR 201.128, intended use is established by labeling and promotional context, including website copy and linked blog content, making the digital footprint as legally consequential as physical labeling.

For regulatory affairs teams, the enforcement action reinforces that FDA's website surveillance program operates as a systematic compliance mechanism, not an ad hoc response. CDER identified the violations through a routine public health review, not a consumer complaint or inspection. The agency cited violations of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a), covering both the unapproved new drug prohibition and the interstate commerce bar. Failure to respond adequately leaves the firm exposed to seizure and injunction without further notice.

The breadth of the cited labeling evidence is operationally relevant for any firm distributing botanical or traditional medicine products online. FDA drew on product detail pages, a blog post titled "How to Reduce Hypertension (Blood Pressure) with Chinese Medicine," and internal hyperlinks connecting editorial content to product listings. Each element contributed to the intended-use determination. QA and regulatory leads at firms with similar digital architectures should audit the full web presence, not only primary product pages, against the intended-use standard.

The warning letter was issued October 23, 2026, and delivered electronically to Director Gretchen Synclaire at the Lake Kiowa, Texas address of record; the firm's response timeline and any corrective commitments will determine whether CDER escalates to formal enforcement action.

Source: FDA CDER via FDA.gov Warning Letters database, October 27, 2026.